Is Autolus Therapeutics PLC halal to invest in?

According to Musaffa's Shariah screening methodology, Autolus Therapeutics PLC (AUTL) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Autolus Therapeutics PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Autolus Therapeutics PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Autolus Therapeutics PLC?

Muslim investors may consider investing in Autolus Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Autolus Therapeutics PLC classified as NOT HALAL?

Musaffa determines the Shariah status of Autolus Therapeutics PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Autolus Therapeutics PLC updated?

The Shariah compliance status of Autolus Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Autolus Therapeutics PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Autolus Therapeutics PLC?

You can check the latest Shariah compliance status of Autolus Therapeutics PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

AUTL Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 01, 2026

Report Source: 2025 Annual Report

Autolus Therapeutics PLC. Stock Analysis AUTL

United States Health Care Small Cap Report: 2025 Annual

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. The firm has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. The company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Key Statistics of Autolus Therapeutics PLC (AUTL)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.53$1.63

Today's Open

$1.58

Volume

1.48M

P/E Ratio (TTM)

52 Week Range

$1.18$2.70

Market Cap

417.84M

Avg. Volume

1.43M

Dividend Yield

Financial Metrics & Statements of Autolus Therapeutics PLC (AUTL)

FAQ's for Autolus Therapeutics PLC (AUTL)

According to Musaffa’s Shariah screening methodology, Autolus Therapeutics PLC (AUTL) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.